The FTC proposes to seek information
from members of the pharmaceutical industry in order to provide a
more complete picture of how generic drug competition has developed
under the Hatch-Waxman Act. The FTC plans to send special orders to
approx. 30 innovator companies (i.e., name-brand drug makers) and
70 generic drug companies to examine agreements, etc., affecting
drug competition.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.